Literature DB >> 29249506

Cognitive and Social Outcomes of Epileptic Encephalopathies.

Katherine C Nickels1, Elaine C Wirrell2.   

Abstract

The term "epileptic encephalopathy" denotes a disorder in which seizures or frequent interictal discharges exacerbate neurocognitive dysfunction beyond what would be expected on the basis of underlying etiology. However, many underlying causes of epileptic encephalopathy also result in neurocognitive deficits, and it can be challenging to discern to what extent these deficits can be improved with better seizure control. Additionally, as seizures in these conditions are typically refractory, children are often exposed to high doses of multiple antiepileptic drugs which further exacerbate these comorbidities. This review will summarize the neurocognitive and social outcomes in children with various epileptic encephalopathies. Prompt, accurate diagnosis of epilepsy syndrome and etiology allows selection of optimal therapy to maximize seizure control, limiting the impact of ongoing seizures and frequent epileptiform abnormalities on the developing brain. Furthermore, mandatory screening for comorbidities allows early recognition and focused therapy for these commonly associated conditions to maximize neurocognitive outcome.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29249506     DOI: 10.1016/j.spen.2017.10.001

Source DB:  PubMed          Journal:  Semin Pediatr Neurol        ISSN: 1071-9091            Impact factor:   1.636


  8 in total

1.  The relation of etiology based on the 2017 ILAE classification to the effectiveness of the ketogenic diet in drug-resistant epilepsy in childhood.

Authors:  Markus Breu; Chiara Häfele; Petra Trimmel-Schwahofer; Wolfgang M Schmidt; Franco Laconne; Julia Vodopiutz; Christoph Male; Anastasia Dressler
Journal:  Epilepsia       Date:  2021-08-28       Impact factor: 6.740

Review 2.  Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies.

Authors:  Elizabeth E Palmer; Katherine Howell; Ingrid E Scheffer
Journal:  Neurotherapeutics       Date:  2021-10-27       Impact factor: 6.088

3.  dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice.

Authors:  Gaia Colasante; Gabriele Lignani; Simone Brusco; Claudia Di Berardino; Jenna Carpenter; Serena Giannelli; Nicholas Valassina; Simone Bido; Raffaele Ricci; Valerio Castoldi; Silvia Marenna; Timothy Church; Luca Massimino; Giuseppe Morabito; Fabio Benfenati; Stephanie Schorge; Letizia Leocani; Dimitri M Kullmann; Vania Broccoli
Journal:  Mol Ther       Date:  2019-09-03       Impact factor: 11.454

Review 4.  Alterations of Neuronal Dynamics as a Mechanism for Cognitive Impairment in Epilepsy.

Authors:  Pierre-Pascal Lenck-Santini; Sophie Sakkaki
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 5.  Calcium channelopathies and intellectual disability: a systematic review.

Authors:  Miriam Kessi; Baiyu Chen; Jing Peng; Fangling Yan; Lifen Yang; Fei Yin
Journal:  Orphanet J Rare Dis       Date:  2021-05-13       Impact factor: 4.123

6.  Scn1a gene reactivation after symptom onset rescues pathological phenotypes in a mouse model of Dravet syndrome.

Authors:  Nicholas Valassina; Simone Brusco; Alessia Salamone; Linda Serra; Mirko Luoni; Serena Giannelli; Simone Bido; Luca Massimino; Federica Ungaro; Pietro Giuseppe Mazzara; Patrizia D'Adamo; Gabriele Lignani; Vania Broccoli; Gaia Colasante
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

Review 7.  Rare and Complex Epilepsies from Childhood to Adulthood: Requirements for Separate Management or Scope for a Lifespan Holistic Approach?

Authors:  Simona Balestrini; Renzo Guerrini; Sanjay M Sisodiya
Journal:  Curr Neurol Neurosci Rep       Date:  2021-11-24       Impact factor: 5.081

Review 8.  Cognitive Impairment in People with Epilepsy.

Authors:  Ajda Novak; Karmen Vizjak; Martin Rakusa
Journal:  J Clin Med       Date:  2022-01-05       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.